These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38937146)

  • 21. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.
    Fransen J; Johnson SR; van den Hoogen F; Baron M; Allanore Y; Carreira PE; Czirják L; Denton CP; Distler O; Furst DE; Gabrielli A; Herrick A; Inanc M; Kahaleh B; Kowal-Bielecka O; Medsger TA; Mueller-Ladner U; Riemekasten G; Sierakowski S; Valentini G; Veale D; Vonk MC; Walker U; Chung L; Clements PJ; Collier DH; Csuka ME; Jimenez S; Merkel PA; Seibold JR; Silver R; Steen V; Tyndall A; Matucci-Cerinic M; Pope JE; Khanna D
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):351-7. PubMed ID: 22052558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction:
    Ann Rheum Dis; 2019 Aug; 78(8):e88. PubMed ID: 31296652
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HAnDE) scale.
    Sibeoni J; Dunogué B; Dupont A; Haiddar D; Benmostefa N; Falissard B; Mouthon L; Révah-Levy A; Verneuil L
    Br J Dermatol; 2022 Jan; 186(1):96-105. PubMed ID: 34355380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.
    Frech T; Hays RD; Maranian P; Clements PJ; Furst DE; Khanna D
    Rheumatology (Oxford); 2011 Jul; 50(7):1280-7. PubMed ID: 21324979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
    J Rheumatol; 2011 Nov; 38(11):2419-27. PubMed ID: 21965635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
    J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
    Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
    Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
    Barbacki A; Baron M; Wang M; Zhang Y; Stevens W; Sahhar J; Proudman S; Nikpour M; Man A;
    Arthritis Care Res (Hoboken); 2023 Mar; 75(3):640-647. PubMed ID: 35226416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis.
    Bruni C; Ngcozana T; Braschi F; Pucci T; Piemonte G; Benelli L; Poli M; Suliman YA; Guiducci S; Bellando-Randone S; Balduzzi S; Grotts J; Denton CP; Rasero L; Montecucco C; Furst DE; Matucci-Cerinic M
    J Rheumatol; 2019 Jun; 46(6):603-608. PubMed ID: 30442833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Gorga M; Mihai C; Soare AM; Dobrotă R; Gherghe AM; Stoica V
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S61-7. PubMed ID: 26316302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of potential classification criteria for systemic sclerosis.
    Johnson SR; Fransen J; Khanna D; Baron M; van den Hoogen F; Medsger TA; Peschken CA; Carreira PE; Riemekasten G; Tyndall A; Matucci-Cerinic M; Pope JE
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):358-67. PubMed ID: 22052658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The assessment of malnutrition and severity of gastrointestinal disease by using symptom-based questionnaires in systemic sclerosis: is it related to severe organ involvement or capillary rarefaction at microcirculation?
    Yalcinkaya Y; Erturk Z; Unal AU; Kaymaz Tahra S; Pehlivan O; Atagunduz P; Direskeneli H; Inanç N
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):127-131. PubMed ID: 32141434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.